Psilocybin

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Retrieved on: 
Tuesday, December 5, 2023
Alternative Medicine, Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Psilocybin, Depression, Safety, NYSE, Efficacy, DMT, DSM-IV codes, NEO, American College, American College of Neuropsychopharmacology, Pharmacology, MBBS, Abstract, Deuterium, DNB, Inc., MDD, Pharmaceutical industry, Patient

“In our study of CYB003 for MDD, we observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose.

Key Points: 
  • “In our study of CYB003 for MDD, we observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose.
  • “As evidenced in each of these presentations, our deuterated programs – psilocybin analog (CYB003) and DMT compounds (CYB004 and SPL028) – are producing highly encouraging results.
  • This is a transformational time for Cybin, with several upcoming value-driving catalysts as we advance our clinical programs.
  • Following on from our recently announced Phase 2 topline efficacy data for CYB003, we expect to have Phase 1 dosing, PK/PD, and safety data for CYB004 and intramuscular dosing data for SPL028 around year end 2023.

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Retrieved on: 
Tuesday, December 5, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, QCL, Psilocybin, Human, Patient, CSE, OTCQB, Partnership, Conference, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.
  • The Company believes the updated stability report for L-130 is significant, as to date, no manufacturer of psilocin has reported a formulation of psilocin stable enough to be administered in a shelf-stable orally available formulation.
  • “L-130 was designed in collaboration with Quality Chemical Laboratories (QCL) based on the needs for a shelf stable oral molecule that can consistently deliver psilocin directly, therefore eliminating the inconsistencies and variabilities seen with psilocybin.
  • This is principally due to psilocybin’s need for first-pass metabolism” stated Philip Young, Chairman and CEO of Lobe Sciences.

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

Retrieved on: 
Wednesday, November 29, 2023
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Psilocybin, Depression, Anxiety, Patient, Addiction, Therapy, Patent, Patent Cooperation Treaty, Pharmaceutical industry

The soon-to-issue patent titled, “Glycosylated Psilocybin Derivatives and Methods of Using,” contains composition of matter and methods of use claims for a family of novel prodrug derivatives of glycosylated psilocybin.

Key Points: 
  • The soon-to-issue patent titled, “Glycosylated Psilocybin Derivatives and Methods of Using,” contains composition of matter and methods of use claims for a family of novel prodrug derivatives of glycosylated psilocybin.
  • The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.
  • “This recent positive decision from the USPTO adds to the intellectual property for our EVM301 Series of molecules.
  • To date, the USPTO has issued nine Notices of Allowance for patent applications claiming compounds in the EVM201 and EVM301 Series, and has granted two patents protecting EB-373, and one patent covering EVM301 series compounds.

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Retrieved on: 
Monday, November 27, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Psilocybin, Medicinal chemistry, Absorption, Depression, American Chemical Society, Prodrug, Toxicology, ACS, Addiction, Journal, Therapy, Anxiety, Journal of Medicinal Chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced a research article describing the development of lead therapeutic candidate, EB-373, a novel psilocin prodrug, will be published on the cover of the Journal of Medicinal Chemistry, a peer-reviewed journal published by the American Chemical Society (ACS).
  • The modifications made in the generation of the library of compounds offer the potential to reduce the duration of the psychedelic experience generated by psilocybin, while maintaining the long-term mental health benefits of psilocin.
  • “The publication in the Journal of Medicinal Chemistry, notably as the issue’s cover article, is a major step in validating the proficiency of Enveric’s innovation engine by demonstrating the comprehensive processes employed to rapidly generate and screen a large library of novel psilocin compounds,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
  • The company expects to complete all enabling preclinical studies by the end of 2023.

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

Retrieved on: 
Friday, November 24, 2023
Biotechnology, General Health, Health, Mental Health, Psilocybin, Depression, New chemical entity, MDMA, Collection, Escherichia coli, Methamphetamine, Addiction, Therapy, Chemical substance, Conference, Anxiety, Synthetic biology, N-methyltransferase, Enzyme, Pharmaceutical industry, Fine chemical, Pioneers of Enver

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the presentation of two posters at the Canadian Chemical Engineering Conference (CSChE 2023) which was held October 29th to November 1, 2023.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the presentation of two posters at the Canadian Chemical Engineering Conference (CSChE 2023) which was held October 29th to November 1, 2023.
  • First, the Enveric research team achieved the production of milligram quantities of pure compounds in small-scale batch fermentations.
  • The purified transamination products were converted to methamphetamine derivatives, including MDMA, by chemical reduction and N-methylation.
  • Using the synthetic biology platform, Enveric researchers were able to produce several previously undescribed, wholly novel products with important activities at target receptors.

Worried about psychedelic use? The Psychedelic Wellness and Healing Initiative of 2024 is the solution

Retrieved on: 
Tuesday, November 21, 2023
Advocacy Group Opinion, Cannabis, Public Policy, Government, Healthcare Reform, Alternative Medicine, Health, State, Local, Natural Resources, Public Safety, Psilocybin, Human, Depression, Safety, Post-traumatic stress disorder, University, Traumatic brain injury, Addiction, Psychotherapy, Patient, Research, Tic disorder, Psychopharmacology, Suicide, Anxiety, Weill Cornell Medicine, PTSD, Columbia University, News, Ecstasy, The Atlantic, Nightclub, Medical device, Pharmaceutical industry

Achieving psychedelic access has become Hodges’ mission, one now embodied in the Psychedelic Wellness & Healing Initiative headed for the 2024 ballot.

Key Points: 

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

Retrieved on: 
Monday, November 13, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Vomiting, Psilocybin, Absorption, Depression, Safety, Clinical trial, DSM-IV codes, Addiction, Metabolism, Therapy, Investigational New Drug, Anxiety, Drug discovery, Patent, ADME, Publication, Pharmaceutical industry

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023.
  • We look forward to several key milestones during the remainder of 2023, including identification of a lead candidate from the EVM301 Series by year-end.
  • We announced favorable results from exploratory animal studies, which demonstrated oral bioavailability and well-tolerated side effects for EB-373.
  • As of September 30, 2023, the Company had cash and cash equivalents of $4.27 million.

MycoMeditations Joins Business Leaders and Government Health Officials in Jamaican Psilocybin Industry Working Group

Retrieved on: 
Monday, December 18, 2023
Psilocybin, Ministry, Bureau, Research, Investment, BSJ, Commerce, Multimedia, Cabinet, Senate, Longmore, Health, Consultant, Growth, Cabinet of Jamaica, Government, Life, Nursing

TREASURE BEACH, Jamaica, Dec. 18, 2023 /PRNewswire-PRWeb/ -- MycoMeditations, a world leader in legal psilocybin-assisted therapy retreats, is pleased to announce the inclusion of CEO Justin Townsend in the Jamaican Psilocybin Industry Working Group (JPIWG), a recently announced official body established by Senator the Honourable Aubyn Hill, Minister of Industry Investment and Commerce (MIIC), under the auspices of the Bureau of Standards of Jamaica (BSJ).

Key Points: 
  • For this growth to have a positive outcome, industry, healthcare professionals, and government will have to coordinate their efforts going forward.
  • "I'm deeply honored on behalf of the MycoMeditations team to be asked to participate in this official working group," said MycoMeditations CEO and Head Facilitator Justin Townsend.
  • The working group is chaired by Senator Dr. Saphire Longmore, a government Senator and Consultant Psychiatrist who facilitates psilocybin use in her practice.
  • "The Jamaica Psilocybin Industry Working Group is being established to study and understand the production and distribution arrangements, recommend suitable methods to facilitate, enable and encourage the standardization of practices and the growth of the psilocybin industry in the country.

Bend Inner Alchemy Poised to Become the Largest Licensed Psychedelic Psilocybin Facilitation Center in Bend, Oregon

Retrieved on: 
Tuesday, December 12, 2023
Psilocybin, Large, Addiction, Alchemy, Depression, Veteran, Research, Mental, PTSD, Nursing

BEND, Ore., Dec. 12, 2023 /PRNewswire/ -- Bend Inner Alchemy, a pioneering wellness center dedicated to psychedelic psilocybin facilitation, announces its ambitious initiative to become the largest licensed facility of its kind in Bend, Oregon. Specializing in the adjuvant treatment of PTSD, treatment-resistant depression, addictions, and various mental health issues, Bend Inner Alchemy is committed to providing innovative and effective solutions for individuals seeking transformative healing experiences.

Key Points: 
  • Bend Inner Alchemy Poised to Become the Largest Licensed Psychedelic Psilocybin Facilitation Center in Bend, Oregon
    BEND, Ore., Dec. 12, 2023 /PRNewswire/ -- Bend Inner Alchemy, a pioneering wellness center dedicated to psychedelic psilocybin facilitation, announces its ambitious initiative to become the largest licensed facility of its kind in Bend, Oregon.
  • In a statement from Dan Wellisch, COO of Bend Inner Alchemy, they express their enthusiasm for the center's role in transforming lives.
  • "At Bend Inner Alchemy, our mission is to provide a safe and supportive environment for individuals seeking profound healing experiences.
  • To support their mission, Bend Inner Alchemy is actively seeking clients to fill their schedule and licensed facilitators to join their experienced team.

ATMA and Cena Life Launch Nationwide Psychedelic-Assisted Therapy Healthcare Network

Retrieved on: 
Thursday, December 7, 2023
Psilocybin, KAP, Depression, Safety, Nursing, SAP, Transcranial magnetic stimulation, Physician, MDMA, Surgeon, Kat, AB, Patient, Ecosystem, Registered nurse, City, ATMA, Special access program, Anxiety, PTSD, Psychedelic drug, Therapy, PAT

CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.

Key Points: 
  • CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.
  • Like the evolving services in the Cena Life practice in Edmonton, the Calgary clinic will offer KaT, rTMS, SAP application support as well as regular psychological counselling services.
  • Together, we aim to create a network that prioritizes patient well-being while fostering a collaborative and supportive environment for practitioners.
  • Practitioners wishing to join The Psychedelic Healthcare Network are encouraged to take the required training for PaT in advance of practice.